Co Inc employee with conspiracy to commit fraud for tipping a contact about potential mergers, including Merck's takeover of Idenix Pharmaceuticals ahead of a public announcement in June, according to a court filing on Tuesday.
Seth Klarman and his fund have hit numerous 'homeruns,' like Micron Technology (NASDAQ: MU ) and Idenix Pharmaceuticals (NASDAQ: IDIX ). So what does this hedge fund manager extraordinaire see in Keryx (NASDAQ: KERX )? Chronic Kidney
late entrants have lost significant time, leverage, and competitiveness since the Merck (NYSE: MRK )/Idenix (NASDAQ: IDIX ) acquisition this summer. We highlight Achillion (NASDAQ: ACHN ) as a top trade idea with our $34 DCF takeover valuation
By Small Pharma Analyst : A few months ago, Merck (NYSE: MRK ) surprised investors by acquiring Idenix (NASDAQ: IDIX ) for $3.85 billion, a 239% premium to its closing share price of the prior day. This was an unexpected acquisition
June 9 (Reuters) - Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.
(Reuters) - Shares of Idenix Pharmaceuticals Inc rose as much as 16 percent on Wednesday, after the company reported positive mid-stage trial data of its hepatitis C drug, suggesting it was closer...
We are no longer providing equity research on Idenix Pharmaceuticals IDIX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
We're leaving our fair value estimate in place after reviewing the results from Idenix Pharmaceuticals ' IDIX three-day dose-escalation study for IDX184 in patients with genotype-1 hepatitis C. Idenix's share price plummeted following
We are maintaining our fair value estimate after reviewing Idenix Pharmaceuticals ' IDIX first-quarter results. Although this marked another quarter in the red for Idenix, the firm was able to increase revenue to
We are maintaining our fair value estimate for Idenix Pharmaceuticals IDIX after the firm announced its decision to out-license its novel HIV treatment, IDX899, to GlaxoSmithKline GSK in order to focus